AbbVievsZoetis

ABBV and ZTS stock compared: price, dividend, valuation and results, from SEC filings.

AbbVie (ABBV) has a market value of $510B and Zoetis (ZTS) $35.9B. Over the last year, with dividends, ABBV moved +26.9% and ZTS -26.7%. The P/E is 49.5 for ABBV and 14.3 for ZTS. Dividend yield: ABBV 2.40%, ZTS 2.49%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$510B

    ZTS$35.9B

    ABBV is 14 times ZTS

  • Revenue, 12 months

    ABBV$66.0B

    ZTS$9.5B

    ABBV is 7.0 times ZTS

  • Net income, 12 months

    ABBV$10.3B

    ZTS$2.5B

    ABBV is 4.1 times ZTS

  • Operating margin

    ABBV32.2%

    ZTS–

  • ROIC

    ABBV25.7%

    ZTS19.5%

    6.2 points apart

  • P/E

    ABBV49.5

    ZTS14.3

    ABBV is 3.5 times ZTS

  • Dividend yield

    ABBV2.4%

    ZTS2.5%

    0.1 points apart

  • 5-year return

    ABBV+193.7%

    ZTS-59.2%

    252.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+193.7%

ZTS-59.2%

10020030020222023202420252026
Returns by period
PeriodABBVWith dividendsZTSWith dividends
1 year since November 17, 2025+26.9%Price +23.2%-26.7%Price -28.3%
3 years since November 17, 2023+130.5%+32.1% a yearPrice +108.5%-49.0%-20.1% a yearPrice -51.3%
5 years since November 17, 2021+193.7%+24.0% a yearPrice +145.7%-59.2%-16.4% a yearPrice -61.6%
10 years since November 18, 2016+616.2%+21.8% a yearPrice +376.4%+87.2%+6.5% a yearPrice +70.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieZTSZoetis

Valuation

ABBVZTS
Valuation
Price$288.30$85.16
Market value$510B$35.9B
Enterprise value (EV)$580B$43.5B
P/E49.514.3
P/E, 5-year median57.032.6
P/B–10.9
EV/EBIT27.313.8
Free cash flow yield3.7%6.2%

Results and growth

ABBVZTS
Results and growth
Revenue, 12 months$66.0B$9.5B
Net income, 12 months$10.3B$2.5B
Free cash flow, 12 months$18.9B$2.2B
Earnings per share, 12 months$5.81$5.93
Revenue growth, year on year8.6%2.3%
Revenue growth a year, past+5.9%over 5 years+7.2%over 5 years
EPS growth a year, past-2.8%over 5 years+12.0%over 5 years

Margins and returns on capital

ABBVZTS
Margins and returns on capital
Gross margin73.7%71.6%
Operating margin32.2%–
Net margin15.7%26.4%
ROIC25.7%19.5%
ROE–67.8%

Balance sheet

ABBVZTS
Balance sheet
Cash$10.8B$1.5B
Total debt$80.9B$9.2B
Net debt / EBITDA3.22.1
Interest cover7.1×13.0×

Dividends and buybacks

ABBVZTS
Dividends and buybacks
Dividend yield2.4%2.5%
Dividend per share, 12 months$6.92$2.12
Dividend growth a year, past+6.6%over 5 years+19.0%over 5 years
Buyback yield0.2%9.0%
Shareholder yield2.6%11.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or ZTS

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Zoetis?

By market value, AbbVie ($510B) is about 14.2 times Zoetis ($35.9B), at today's prices.

How did ABBV and ZTS stock do over the last 10 years?

Since November 18, 2016, ABBV's price moved +376.4% and ZTS's +70.7%. With dividends: ABBV +616.2% (+21.8% a year), ZTS +87.2% (+6.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or ZTS?

The dividend yield at today's price is 2.40% for AbbVie and 2.49% for Zoetis. Over the last twelve months they paid $6.92 and $2.12 per share.

What is the P/E of ABBV and ZTS?

At today's price, the P/E is 49.5 for ABBV and 14.3 for ZTS. The median of the last five years was 57.0 and 32.6, which shows where each stands against its own past.

Which has the higher profit margins, AbbVie or Zoetis?

Over the last twelve months, the net margin was 15.7% for AbbVie and 26.4% for Zoetis, and the operating margin 32.2% and –. Revenue was $66.0B and $9.5B.

Which is the better investment, AbbVie or Zoetis?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.